A panel discussion during the eyeforpharma Philadelphia 2020 virtual conference is set to discuss ways to incentivize drug innovation during a pandemic.
The discussion will feature National Pharmaceutical Council CSO Robert Dubois and representatives from the Institute for Clinical and Economic Review (ICER) and Biogen.
In a blog post on the upcoming panel, Dubois writes that “the health care system, as a whole, is facing unprecedented times.”
” … While the priority is on finding a cure or vaccine for COVID-19, we must not forget that scientific discovery is still advancing across the entire health care sector,” Dubois writes. “How can we continue to support and incentivize innovation during this public health crisis and potentially the next one?”
To read Dubois’ full post on LinkedIn, click here.